San Marino vs Solomon Islands: Immunization, Hib3
San Marino
87.0%
in 2024
Solomon Islands
87.0%
in 2024
San Marino rank
117th
Solomon Islands rank
117th
Immunization, Hib3 over time
- San Marino
- Solomon Islands
How they compare
San Marino currently reports 87.0% against 87.0% in Solomon Islands, a difference of 0.0%.
The two have swapped places 7 times across 17 shared years of data; in 2008 it was San Marino ahead.
San Marino ranks 117th and Solomon Islands ranks 117th of 191 countries.
Across the 3 decades both report, San Marino averaged higher in 2 and Solomon Islands in 1.
Head to head by decade
| Decade | San Marino | Solomon Islands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 89.0% | 88.0% | 1.0% | San Marino |
| 2010s | 86.3% | 87.4% | 1.1% | Solomon Islands |
| 2020s | 89.0% | 88.2% | 0.8% | San Marino |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, San Marino or Solomon Islands?
- San Marino, at 87.0% against 87.0% in Solomon Islands as of 2024.
- What is the difference in immunization, hib3 between San Marino and Solomon Islands?
- 0.0%, with San Marino ahead.
- How many years of comparable data are there for San Marino and Solomon Islands?
- 17 years are reported by both, from 2008 to 2024.
- How do San Marino and Solomon Islands rank globally for immunization, hib3?
- San Marino ranks 117th and Solomon Islands ranks 117th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.